Xilio Therapeutics, Inc. (XLO) Financials

XLO Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 77.8 million 25.3 million
2023-06-30 92.4 million 25.0 million
2023-03-31 111.5 million 26.7 million
2022-12-31 139.2 million 33.5 million

XLO Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -13.4 million 1.9 million
2023-06-30 -16.9 million 1.8 million
2023-03-31 -25.4 million 1.8 million
2022-12-31 -18.7 million 1.8 million

XLO Net Income

No data available :(

XLO Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 59.8 million - 9.4 million
2023-06-30 75.4 million - 9.7 million
2023-03-31 93.3 million - 9.9 million
2022-12-31 120.4 million - 10.1 million

XLO Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 27.5 million
2023-06-30 27.5 million
2023-03-31 27.4 million
2022-12-31 27.4 million

XLO Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 - 11.1 million 6.3 million -
2023-06-30 316000 13.2 million 6.9 million -
2023-03-31 170000 16.1 million 7.4 million -
2022-12-31 509000 15.0 million 8.2 million -

XLO Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 460000
2023-06-30 - 492000
2023-03-31 - 499000
2022-12-31 - 489000

XLO

Price: $1.05

52 week price:
0.49
3.45

Earnings Per Share: -2.96 USD

P/E Ratio: -0.22

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 18100

Market Capitalization: 35.2 million

Links: